Impact of COVID-19 Disease in Early Breast Cancer Management: A Summary of the Current Evidence.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 35594492.
- Also identified by DOI 10.1200/GO.21.00357 and PMC identifier 9173577.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
An expert panel on breast cancer and COVID-19 disease was convened to address the impact of the COVID-19 pandemic for early breast cancer (eBC) management. To ensure that the most clinically relevant information was addressed, essential information was drawn from several of the latest national and international guidelines and another technical document. The expert panel met in five virtual closed sessions from November 2020 to May 2021 to consult on the relevant data from evidence-based results. The data gathered were discussed on an online platform. This article reports the expert panel's highlights of these meetings' discussions. In addition, it provides practical recommendations covering topics regarding diagnosis, treatment, and management of patients with eBC in clinical settings routinely encountered by health care professionals amid the COVID-19 pandemic. This article provided guidance on several topics regarding eBC management amid the COVID-19 pandemics to inform safer care practices.
Medical subject headings
- Breast Neoplasms
- COVID-19